Novartis Investigative Site

Salta A4400BKZ

0 studies enrolling now · 10 studies all time

What they study most

Acute Heart Failure, Asthma, Atherosclerosis, Chronic Spontaneous Urticaria, Multiple Sclerosis, Pulmonary Disease, Chronic Obstructive, Relapsing Forms of Multiple Sclerosis

Studies at this site

• Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma — Completed
• A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines. — Completed
• Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab — Stopped early
• Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients — Completed
• Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies — Completed
• Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis — Completed
• Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment — Stopped early
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
• Global Non-interventional Heart Failure Disease Registry — Stopped early
• Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF — Completed